EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Prevalence, treatment and burden of chronic spontaneous urticaria in five European countries

Maria-Magdalena Balp iD, Kathryn Krupsky, Shaloo Gupta, Clementine Lienhard, Ravneet K Kohli, Dhaval Patil, Florence Tétart, John Reed, Tariq El-Shanawany

Journal of the European Academy of Dermatology and Venereology · 2025-10 · 39 (10) · 1806-1817

DOI: 10.1111/jdv.20772 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 05.06.2025. Verfasst von Maria-Magdalena Balp und 8 weiteren Autor:innen. Beteiligte Einrichtung: Novartis Pharma AG, Basel, Switzerland. Hauptthemen laut MEDLINE: Chronic Urticaria, Cost of Illness. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novartis Pharma AG, Basel, Switzerland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Although chronic spontaneous urticaria (CSU) is a common form of chronic urticaria (CU), its impact on overall disease burden and treatment patterns in real‐world settings requires further understanding.

Objectives

To assess prevalence, treatment patterns, disease profile and burden in patients with CSU in five European countries (EU5: France, Germany, Italy, Spain and the United Kingdom [UK]).

Methods

Data were from the 2020 EU5 National Health and Wellness Survey (NHWS). Age‐ and sex‐adjusted prevalence of diagnosed CSU was estimated for the overall EU5 and by country. Sociodemographic, health characteristics, treatment history and dermatology‐specific quality of life were described for the CSU cohort. Patient‐reported outcomes, including the Short Form 12‐item Survey (SF‐12v2) mental (MCS), physical component (PCS) summary scores; SF‐6D; EQ‐5D; General Anxiety Disorder‐7 (GAD‐7); Patient Health Questionnaire‐9 (PHQ‐9); Work Productivity and Activity Impairment (WPAI) and healthcare resource use (HRU), were summarized for the CSU cohort, overall and by country and descriptively compared to the full NHWS sample.

Results

Of 62,319 respondents, 794 patients were diagnosed with CU. Among these, 519 had CSU. Weighted prevalence of CSU in EU5 was 0.92%. Roughly half of the CSU cohort was treated with prescription and/or over‐the‐counter medication. Among the CSU cohort, 36.7% of patients experienced a very large to extremely large disease impact (Dermatology Life Quality Index [DLQI] > 10); most had poorly controlled disease (71.6%). Mean MCS, PCS, SF‐6D and EQ‐5D scores were worse for CSU versus the full NHWS sample. A higher proportion of the CSU cohort, versus the full NHWS sample, had GAD‐7 and PHQ‐9 scores of ≥5. Mild–severe anxiety, depression and WPAI scores were highest in the UK. HRU was higher in the CSU cohort than in the full NHWS sample.

Conclusions

CSU negatively impacts patients' lives. Yet, many patients remain inadequately treated and uncontrolled. These results highlight a need for comprehensive care approaches to improve patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chronic UrticariaCost of IllnessHumansMaleFemalePrevalenceMiddle AgedAdultQuality of LifeEuropePatient Reported Outcome MeasuresAgedYoung Adult

Autor:innen und Institutionen

  • Novartis Pharma AG, Basel, Switzerland.
  • Oracle Life Sciences, Austin, Texas, USA.
  • Novartis Pharmaceuticals France, Prix & Eco Sante PC/CC Vaccines, Paris, France.
  • Novartis Healthcare Pvt Ltd., Value & Access, Hyderabad, India.
  • Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
  • Department of Dermatology, CHU De Rouen, Rouen, France.

ORCID-Profile: Maria-Magdalena Balp

Förderung

  • Novartis Pharma AG, Basel, Switzerland

Zitieren

APA

Balp, M. M., Krupsky, K., Gupta, S., Lienhard, C., Kohli, R. K., Patil, D., Tétart, F., Reed, J., & El-Shanawany, T. (2025). Prevalence, treatment and burden of chronic spontaneous urticaria in five European countries. Journal of the European Academy of Dermatology and Venereology, 39(10), 1806-1817. https://doi.org/10.1111/jdv.20772

Vancouver

Balp MM, Krupsky K, Gupta S, Lienhard C, Kohli RK, Patil D, et al. Prevalence, treatment and burden of chronic spontaneous urticaria in five European countries. Journal of the European Academy of Dermatology and Venereology. 2025;39(10):1806-1817. doi:10.1111/jdv.20772

BibTeX
@article{Balp2025,
  author = {Balp, Maria-Magdalena and Krupsky, Kathryn and Gupta, Shaloo and Lienhard, Clementine and Kohli, Ravneet K and Patil, Dhaval and Tétart, Florence and Reed, John and El-Shanawany, Tariq},
  title = {Prevalence, treatment and burden of chronic spontaneous urticaria in five European countries},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2025},
  volume = {39},
  number = {10},
  pages = {1806--1817},
  doi = {10.1111/jdv.20772}
}
Kostenlos starten →